该药为E-选择素抑制剂,以内皮细胞为靶点,阻断骨髓细胞与白血病髓样细胞的粘附。
在对 388 名复发/难治性急性髓系白血病 (AML) 患者进...查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011861 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 20:35
$Glycomimetics(GLYC)$ 8-K Current report, items 5.03, 5.07, and 9.01 Accession Number: 0001558370-24-006459 Act: 34 Size: 320 KB 网页链接查看全文
Glycomimetics(GLYC)05-07 04:05
$Glycomimetics(GLYC)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001558370-24-006793 Act: 34 Size: 7 MB 网页链接查看全文
Glycomimetics(GLYC)06-04 21:35
$Glycomimetics(GLYC)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001558370-24-008882 Act: 34 Size: 8 MB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011872 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011867 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011862 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011869 Size: 5 KB 网页链接查看全文
Linktu2021-04-13 02:32
$Glycomimetics(GLYC)$ 谈谈我对这个股票的看法,这是TD Ameritrade券商公布的数据76.78% 的机构持有,为什么这么多机构持有?股价跌不表示这个股票不好,这么多大机构看好骨肉瘤的药,理由是什么,看看这其中一个在10 号公布的数据,不管散户们怎么看,它是很棒的利好,机构们看好,我也看好,良...查看全文
Linktu2021-04-11 08:04
$Glycomimetics(GLYC)$ 这是一个利好:
( Sipkins博士将公开临床前证据,表明GMI-1359可能会增强对肿瘤的免疫识别。小鼠转移性乳腺癌模型的海报中的数据表明,原发肿瘤部位的免疫抑制单核细胞MDSC减少,原发肿瘤和骨转移部位的CD8 / Treg比值显着增加。这些关于免疫细胞重新分布的发现强烈暗...查看全文
Linktu2021-04-11 08:00
$Glycomimetics(GLYC)$ GlycoMimetics,Inc.(纳斯达克股票代码:GLYC)今天宣布,在杜克大学癌症中心进行的GMI-1359的1b期临床试验表明,在接受治疗的最初两名患者中,有靶向作用,免疫激活和细胞动员的证据。该公司的E-选择素和CXCR4的双重拮抗剂。Dorothy Sipkins医学博士,杜克大学医学院药理...查看全文
$Glycomimetics(GLYC)$ 8-K Current report, item 3.01 Accession Number: 0001558370-24-009508 Act: 34 Size: 173 KB 网页链接
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017978 Size: 6 KB 网页链接
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017623 Size: 5 KB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, item 5.02 Accession Number: 0001558370-24-009140 Act: 34 Size: 182 KB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001558370-24-008882 Act: 34 Size: 8 MB 网页链接
$Glycomimetics(GLYC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-007632 Act: 34 Size: 4 MB 网页链接
$Glycomimetics(GLYC)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001072613-24-000441 Act: 34 Size: 121 KB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001558370-24-006793 Act: 34 Size: 7 MB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, items 5.03, 5.07, and 9.01 Accession Number: 0001558370-24-006459 Act: 34 Size: 320 KB 网页链接
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011860 Size: 5 KB 网页链接